intractable insomnia
Conditions
Interventions
low-dose experimental group:Low-dose remimazolam + dexmedetomidine group
high-dose experimental group:High-dose remimazolam + dexmedetomidine
Sponsors
Zhejiang Provincial People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. ASA I or II, aged 18–60, with a body mass index of 20–30 kg/m². 2. Patients scheduled for treatment of chronic insomnia (insomnia lasting more than 6 months). 3. Meet the DSM-5 diagnostic criteria for insomnia and voluntarily sign the informed consent before anesthesia, able to accept this experimental method, and willing to participate as a subject.
Exclusion criteria
Exclusion criteria: 1. Those with contraindications to imaging examinations, such as non-magnetic resonance compatible metal implants, claustrophobia, pregnancy, etc. 2.Those with acute or chronic infections, severe systemic diseases, abnormal bleeding and coagulation, and tumor diseases;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Insomnia Severity Index (ISI) Score;The variations of numbers and graphs in multimodal images;The effective dose of remimazolam induction;Hamilton Anxiety Rating Scale (HAM-A);Hamilton Depression Rating Scale (HAM-D);Pittsburgh Sleep Quality Index (PSQI); | — |
Secondary
| Measure | Time frame |
|---|---|
| duration of treatment;heart rate;blood pressure;incidence of adverse reactions;dosage;oxygen saturation; | — |
Countries
China
Contacts
Public ContactLang Junhui
Zhejiang Provincial People's Hospital
Outcome results
None listed